



Aerpio Therapeutics to Present at the 14th Annual Needham Healthcare Conference

Needham Healthcare Conference 2015

April 09, 2015 08:30 AM Eastern Daylight Time

CINCINNATI--(BUSINESS WIRE)--Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for vascular disorders with a focus on diseases of the eye, today announced that President and CEO Joseph Gardner, Ph.D., will present at the 14th Annual Needham Healthcare Conference on Tuesday, April 14th, 2015 at 10:20 am EDT. Dr. Gardner will provide a corporate overview and business update, including anticipated milestones for 2015, and will also be available to participate in one-on-one meetings with registered attendees.

About Aerpio Therapeutics

Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for vascular disorders with a focus on diseases of the eye. Aerpio is a leader in the development of small molecule drugs based on Tie2 activation. The Company's lead program, AKB-9778, is a first-in-class stabilizer of the Tie2 pathway and is in clinical development for diabetic eye disease and retinal vein occlusion. More information is available at www.aerpio.com.

Contacts

Aerpio Therapeutics, Inc.

Dhaval Desai

Vice President of Medical Affairs

ddesai@aerpio.com

or

Burns McClellan on behalf of Aerpio Therapeutics

Justin Jackson, 212-213-0006

jjackson@burnsmc.com